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Abstract
Background: Neonatal withdrawal secondary to in utero opioid exposure is a growing global concern stressing the
psychosocial well-being of affected families and scarce hospital resources. In the ongoing search for the most
effective treatment, randomized controlled trials are indispensable. Consistent outcome selection and measurement
across randomized controlled trials enables synthesis of results, fostering the translation of research into practice.
Currently, there is no core outcome set to standardize outcome selection, definition and reporting. This study
identifies the outcomes currently reported in the literature for neonates experiencing withdrawal following opioid
exposure during pregnancy.
Methods: A comprehensive literature search of MEDLINE, EMBASE and Cochrane Central was conducted to identify
all primary research studies (randomized controlled trials, clinical trials, case-controlled studies, uncontrolled trials,
observational cohort studies, clinical practice guidelines and case reports) reporting outcomes for interventions
used to manage neonatal abstinence syndrome between July 2007 and July 2017. All “primary” and “secondary”
neonatal outcomes were extracted by two independent reviewers and were assigned to one of OMERACT’s core
areas of “pathophysiological manifestation”, “life impact”, “resource use”, “adverse events”, or “death”.
Results: Forty-seven primary research articles reporting 107 “primary” and 127 “secondary” outcomes were
included. The most frequently reported outcomes were “duration of pharmacotherapy” (68% of studies, N = 32),
“duration of hospital stay” (66% of studies, N = 31) and “withdrawal symptoms” (51% of studies, N = 24). The
discrepancy between the number of times an outcome was reported and the number of articles was secondary to
the use of composite outcomes. Frequently reported outcomes had heterogeneous definitions or were not defined
by the study and were measured at different times. Outcomes reported in the literature to date were mainly
assigned to the core areas “pathophysiologic manifestations” or “resource use”. No articles reported included parent
or former patient involvement in outcome selections.
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Conclusions: Inconsistent selection and definition of primary and secondary outcomes exists in the present
literature of pharmacologic and nonpharmacologic interventions for managing opioid withdrawal in neonates. No
studies involved parents in the process of outcome selection. These findings hinder evidence synthesis to generate
clinically meaningful practice guidelines. The development of a specific core outcome set is imperative.
Keywords: Neonatal withdrawal syndrome, Neonatal abstinence syndrome, Neonatal opioid withdrawal syndrome,
Core outcome set, Opioid exposed newborn baby, Maternal opioid use disorder,
Background
Neonatal abstinence syndrome (NAS) is a postnatal
withdrawal syndrome that occurs after fetal exposure to
substances (for example, opioids, antidepressants and
stimulants) in utero [1]. Among neonates exposed to
opioids in utero, 55–94% [2] will demonstrate the clin-
ical manifestations of NAS which predominantly involve
central nervous system irritability, autonomic dysregula-
tion and gastrointestinal dysfunction [1]. Typically,
opioid-exposed neonates are observed in hospital for 3
to 7 days for the development of NAS symptoms prior
to discharge [2]. Approximately 50–80% of these infants
exhibit moderate to severe withdrawal symptoms requir-
ing pharmacologic management in addition to support-
ive nonpharmacologic interventions [3, 4]. The use of
pharmacotherapy varies depending on whether the neo-
nate meets the “treatment threshold” per the diagnostic
criteria utilized (i.e., the Finnegan Scale, Lipsitz score, or
the Eat Sleep Console model) which varies between cen-
ters. The average length of stay for a neonate experien-
cing NAS is 16–23 days, accounting for monitoring and
stabilization of symptoms with pharmacotherapy [5].
In recent years, NAS has become a global concern with
increasing prevalence rates ranging between 2.7 and 5.8
per 1000 live births [5–7]. In the USA between 2009 and
2012, the aggregate hospital charges for NAS increased
from $732 million to $1.5 billion dollars [5]. A similar
trend is documented in Canada, with tripling of the daily
hospital beds occupied by neonates with NAS from
19.7 beds in 2003 to 69.4 beds in 2014 [8]. The actual bur-
den of disease is likely inaccurate given the complexity of
exposure, genetic factors that may increase the risk for
withdrawal, patterns of recognition and reporting, along
with extensive variability in regional substance misuse and
diagnostic criteria. The extent to which different preva-
lence rates vary by hospital related to recognition or re-
cording requires further investigation. Robust evidence is
lacking on the long-term consequences (i.e., medical, neu-
rodevelopmental or psychosocial) for the individual who
has experienced NAS [3]. The current increase in NAS
diagnosis is believed to be multifactorial and driven by im-
provements in screening, awareness and practice guide-
lines, and by the increasing rates of both illicit drug use
and prescription of opioids/psychotropic medications
during pregnancy [9, 10]. Historically, NAS presentation
was primarily due to in utero opioid exposure [3]. Neo-
natal opioid withdrawal syndrome (NOWS) is a subset of
NAS reflecting neonatal withdrawal following exposure to
opioids in pregnancy. The later, more specific definition
has recently been adopted and may not be reflected in
previously published reports. As polysubstance exposures
during pregnancy are becoming more prevalent, report-
edly as high as 65% in one study [11] and even higher with
the inclusion of alcohol and tobacco, NAS is becoming an
increasingly complex syndrome with less predictable time
of onset, severity and response to pharmacologic therapy
[12, 13]. From the clinical perspective, there has been a
paradigm shift in infant assessment and treatment initi-
ation (using thresholds evaluated by subjective features of
withdrawal to using the Eat, Sleep, Console method) [14]
and the emergence of novel pharmacokinetic- and
pharmacodynamic-based dosing protocols [15]. The ever-
increasing burden of disease, evolving complexity in pres-
entation and changing pharmacotherapy initiation models
have led to a growing interest in NAS research from scien-
tists, clinicians and policy makers.
In 2013, the World Health Organization evaluated all
available evidence on identifying and managing neonates
withdrawing from in utero substance exposure. The
quality of evidence behind the recommendations was de-
termined to be “very low” per the Grading of Recom-
mendations, Assessment, Development and Evaluations
framework [16, 17]. This paucity of evidence is reflected
in the heterogeneity of clinical care for infants at risk for
NAS. National studies in Canada [18], the USA [19], the
UK and Ireland [20] demonstrated significant variability
in NAS/NOWS assessment tools, types and doses of opi-
oids utilized, and addition of adjuvant agents across neo-
natal intensive care units. Current economical
assessments continue to show a substantial rise in NAS-
related morbidity and costs [21–23]. With stakeholders
examining the same topic through various lenses from
bench-to-bedside to policy development, it is imperative
to establish clinically relevant and standardized outcome
measures. At present, there is no consensus on what to
measure nor consistent units of measurement in re-
search and quality improvement initiatives on neonates
with NAS/NOWS.
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The purpose of this study is to evaluate consistency in
outcomes reported in all observational and interven-
tional studies of neonates exposed to opioids during
pregnancy who develop withdrawal (NAS/NOWS). We
will assess neonatal outcomes reported in all studies in-
vestigating pharmacological and nonpharmacological in-
terventions for infants that were exposed to opioids
(such as methadone, buprenorphine, oxycodone, or pre-
scription opioids with or without concomitant use of
other illicit substances) in utero and who are diagnosed
with NAS or NOWS in the postnatal period.
Methods
Protocol and registration
This initiative has been prospectively registered with
Core Outcome Measures in Effectiveness Trials
(COMET) [24]. The complete study protocol has been
published [25] and is available at https://trialsjournal.
biomedcentral.com/articles/10.1186/s13063-016-1666-9
Eligibility criteria
Primary research studies including randomized con-
trolled trials, clinical trials, case-controlled trials, uncon-
trolled trials, observation cohort studies, clinical practice
guidelines, and case reports of any interventions used to
manage NAS/NOWS were analyzed. For the purpose of
this review, studies of pharmacological and nonpharma-
cological management of neonates exposed to opioids
(including methadone, buprenorphine, oxycodone, pre-
scription opioids) in utero who are diagnosed with NAS
were included. We included all co-exposures based on
the rationale that they commonly occur and that ICD 9
diagnostic coding does not separate withdrawals related
only to opioids. All publications identified from the pub-
lished search strategy between January 2007 and June
2017 were included. The rationale behind the time re-
striction is that a Cochrane review was published in
2009 encompassing studies reported prior to 2007 and a
shift in clinical practice away from ubiquitous use of
deodorized dilution of opium [26]. The steering commit-
tee felt that there was limited value in evaluating what
outcome measures were used before widespread use of
the Finnegan assessment tools and oral morphine treat-
ment weaning.
Search strategy
The search strategy (Additional file 1) was developed in
conjunction with a reference librarian at the Hospital for
Sick Children on Ovid MEDLINE 1946 to present with
daily update, Ovid MEDLINE in-process and other non-
indexed citations. The search was also applied to
EMBASE and Cochrane Central on 6 June 2019. The lat-
est Cochrane review was published in 2010. Reference
lists of four recently published systematic reviews of
NAS were evaluated. In addition to the electronic search
strategy completed as above, ClinicalTrials.gov was
reviewed and identified 37 studies for ongoing trials re-
lated to NAS. Bibliographies of all included studies and
systematic reviews were reviewed to identify relevant ar-
ticles not generated in the search. In addition, the steer-
ing committee reviewed the list of articles to ensure
comprehensiveness and to provide related articles not
identified by the search strategy.
Study selection
Two independent reviewers (LEK and SM) screened ti-
tles and abstracts resulting from all the search strategies
in EndNote X6. For studies that were deemed eligible by
title and abstract, full-text articles were obtained. Full-
text articles were critically reviewed independently (LEK,
SM and FS) to assess eligibility. Studies published prior
to 2007 were excluded as most studies focused on the
use of tincture of opium which is no longer utilized for
the management of NAS. Reasons for exclusions were
documented. Any disagreement in study eligibility cri-
teria was resolved through discussion and consensus or
by consulting the principle investigator (LEK). Studies
were excluded if they did not describe NAS health out-
comes or if the full text was not available in a language
mastered by our team (English, French, Spanish or
Dutch). Only infants with an NAS diagnosis (irrespective
of the diagnostic tool utilized) following known opioid
exposure in utero were included regardless of concomi-
tant substance exposure.
Data extraction
Data were extracted independently and in duplicate by
two reviewers (SM and FS). Disagreements were re-
solved by consultation with the principal investigator
(LEK). A standardized table was utilized for data extrac-
tion which included the following information: year of
publication, corresponding author and contact informa-
tion, study design (randomized controlled tried, cohort
study, quality improvement, case series, case report),
NAS intervention type (pharmacologic or nonpharmaco-
logic), intervention group, control group, randomization,
sample size, study objective in full text, method of NAS
diagnosis, frequency of monitoring NAS symptoms, dur-
ation of exposure, type of maternal exposure (metha-
done, suboxone, buprenorphine, illicit opioids,
benzodiazepines, cocaine, and so forth), study inclusion
criteria, study exclusion criteria, primary outcomes, sec-
ondary outcomes, and justification for outcome choice.
An outcome was included as reported if it was included
in the methods, results or discussion sections. The out-
come was placed under “primary outcome” if it was ex-
plicitly stated as the primary outcome in the study, it
was the only outcome reported, or it was implicit in
Shan et al. Trials          (2020) 21:262 Page 3 of 14
their data reporting (i.e., used in the sample size calcula-
tion). Composite outcome measures were separated to
gauge the full breadth of definitions utilized in primary
research studies.
Categorizing similar outcomes
Considerable heterogeneity in the terminology used to
report outcomes was noted during the data extraction.
Outcomes of similar themes were grouped during the
data analysis process. For instance, “days of infant opioid
treatment”, “length of infant methadone therapy” and
“duration of infant oral morphine therapy” were all in-
cluded in the outcome category “duration of pharmaco-
therapy for NAS”.
Assignment of outcome category to core areas
Outcomes reported as either primary and/or secondary
were assigned to one of the four core areas plus adverse
events as defined in OMERACT Filter 2.0 [27]. OMER-
ACT is a conceptual framework to ensure that a com-
prehensive set of outcomes is selected to formulate a
core outcome set (COS). Its core areas encompass con-
tent that is measurable in a trial that include both
patient-centered and intervention-specific information.
These four core areas include “death”, “life impact”, “re-
source use” and “pathophysiologic manifestations”.
OMERACT recommends that “adverse events” should
be measured within the core areas [27].
Results
The search strategy (Additional file 1) identified 2935
unique articles for screening (Fig. 1); a total of 47 ori-
ginal research publications met the specified inclusion
criteria and were included in this review. Reference lists
for three recently published NAS reviews and systematic
reviews were evaluated and no additional relevant arti-
cles were identified [1, 3, 28]. The characteristics of the
included studies are outlined in Table 1. The 47 articles
published outcomes from ten randomized controlled tri-
als, 21 retrospective cohort studies, five prospective co-
hort studies, one qualitative analysis, three case series,
and one case report. The remaining studies utilized
quality improvement methodologies (four studies), com-
bined retrospective and prospective cohort analysis (one
study), and a prospective within-subject analysis (one
study). There were no disagreements in the study
Fig. 1 Prisma article selection flow diagram. NAS neonatal abstinence syndrome
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Table 1 Characteristics of included studies
First author (ref.) Year Intervention
type
Intervention Study type Region of
origin
Sample
Size
Ebner [29] 2007 P Morphine PCS Austria 53
Abrahams [30] 2007 NP Rooming-in RCS Canada 106
Mazurier [31] 2008 P Morphine CS France 37
Colombini [32] 2008 P Morphine PCS France 22
Jansson [33] 2008 NP Breast feeding PCS USA 16
Kraft [34] 2008 P Sublingual buprenorphine RCT USA 26
Agthe [35] 2009 P Clonidine RCT USA 80
Leikin [36] 2009 P Clonidine CS USA 14
Abrahams [37] 2010 NP Rooming-in RCS Canada 952
Saiki [38] 2010 NP Postnatal ward RCS UK 60
Esmaeili [39] 2010 P Clonidine and chloral hydrate RCS Germany 133
O’Mara [40] 2010 P Clonidine CR USA 1
Isemann [41] 2011 NP Breastfeeding RCS USA 128
Kraft [42] 2011 P Sublingual buprenorphine RCT USA 24
McQueen [43] 2011 NP Breastfeeding RCS Canada 28
Schwartz [44] 2011 NP Auricular acupressure RCT USA 76
Backes [45] 2012 NP Outpatient weaning RCS USA 121
Filippelli [46] 2012 NP Noninsertive acupuncture CS USA 54
Murphy-Oikonen
[47]
2012 NP Clinical practice guideline RCS Canada 90
O’Connor [48] 2013 NP Breastfeeding RCS USA 85
Welle-Strand [49] 2013 NP Breastfeeding Mixed method (RCS and
PCS)
Norway 124
Surran [50] 2013 P Clonidine adjunct RCT USA 68
Hall [51] 2014 P Weaning protocols for morphine, methadone,
buprenorphine
RCS USA 547
Bhatt-Mehta [52] 2014 P Methadone RCS USA 60
Smirk [53] 2014 NP Home-based detoxification RCS Australia 118
Asti [54] 2015 NP Implementation of standardized protocol QI USA 92
Hall [55] 2015 P Methadone weaning protocol PCS USA 360
Liu [56] 2015 NP Breastfeeding RCS Australia 194
Hall [57] 2015 P Standardized weaning protocol RCS USA 981
Raith [58] 2015 NP Laser acupuncture RCT Austria 28
Brown [59] 2015 P Methadone RCT USA 31
Bada [60] 2015 P Morphine RCT USA 31
Lee [61] 2015 NP Combined in/outpatient RCS USA 139
Nayeri [62] 2015 P Phenobarbital RCT Iran 60
Young [63] 2015 P Oral morphine RCS USA 26
Newman [64] 2015 NP Rooming-in PCS Canada 45
Kelly [65] 2015 NP Home weaning RCS Canada 80
Hall [66] 2016 P Buprenorphine RCS USA 201
Ibach [67] 2016 P Methadone RCS USA 50
Hahn [68] 2016 NP Massage Qualitative thematic
analysis
USA 8
Holmes [69] 2016 NP Rooming-in QI USA 163
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inclusion process that could not be resolved through
discussion.
The characteristics of the included publications are dis-
played in Table 1. The country of origin for the studies in-
cluded the USA (n = 31), Canada, (n = 6), France (n = 2),
Australia (n = 2), Austria (n = 2), Norway (n = 1), the UK
(n = 1), Iran (n = 1) and Germany (n = 1). Of the included
studies, 21 evaluated pharmacologic regimens while 26
assessed nonpharmacologic interventions for NAS. The
median sample size was 78 neonates (range 1 to 345).
Description of outcomes reported in primary research
studies
A total of 107 primary outcomes and 127 secondary out-
comes were reported in the included 47 studies. Of these
outcomes, 67 primary and 94 secondary outcomes, re-
spectively, were unique ‘terms’ that were not used in any
other study. The individual outcomes were mapped into
outcome categories as illustrated in Table 2. For ambigu-
ous reported outcomes, the full text of the article was
reviewed to determine how it was measured to classify
the outcome into an outcome category. For instance, “ef-
fectiveness of methadone for the treatment of NAS” was
the primary outcome in one article [52]. The surrogate
markers of “effectiveness of methadone for the treatment
of NAS” were “time since need for pharmacological
treatment was established”, “methadone dose in mg/kg/
day”, “methadone dosing interval” and “Lipsitz scores”.
These surrogate markers were separated as individual
outcomes to accurately reflect specific outcome mea-
sures. Fifteen outcomes were mapped into the outcome
category of “miscellaneous single outcomes”. The most
frequently reported outcome category was “duration of
hospital stay”, which was reported in 30 primary re-
search studies (63.8%) as a primary or secondary out-
come. Twenty-one of these primary research studies
reported “duration of hospital stay” as a primary out-
come measure. As noted in Table 2, there is heterogen-
eity in how the most commonly reported outcome
(duration of hospital stay) is measured in research stud-
ies using six different definitions. Figure 2 demonstrates
the distribution of primary and secondary outcome
terms across individual research studies. There is also a
wide range in the number of outcomes reported (1 to
12) per study. For instance, only seven (15%) of studies
reported all three of the most frequently reported out-
come categories (duration of hospital stay, duration of
pharmacotherapy, and presence of NAS symptoms).
Heterogeneity of outcome selection is reflected by the
large number of primary (53/107) and secondary (76/
127) outcomes that were only reported in a single study.
The timing of outcome measurement was poorly re-
ported across studies and was inconsistent. For example,
neurobehavior was measured in two studies: one study
reported Bayley Scale scores at 1 year and the second re-
ported the NICU Network Neurobehavioral Scale
(NNNS) at 5–7 days old and at 44 weeks postmenstrual
age. Withdrawal severity scoring outcomes were re-
ported after 1 week of treatment, six times daily, and
“according to hospital policies”. Training of outcome as-
sessors was only mentioned for seven primary outcomes
and six secondary outcomes. Training protocols were
only provided in one study. Outcome assessors were de-
scribed for 12 primary and 14 secondary outcomes, and
were mostly clinicians (physicians and/or nurses, n = 9/
12 and n = 12/14, respectively). The study design may
affect the outcomes reported as demonstrated in Table 3.
For the most commonly utilized study designs such as
retrospective cohort studies (n = 21), randomized con-
trolled trials (n = 10) and prospective cohort studies (n =
5) there was less variability in outcomes selected com-
pared to quality improvement studies and case reports.
Cohort studies and clinical trials reported “duration of
hospital stay” and “duration of pharmacotherapy” most
frequently. Qualitative improvement studies also re-
ported length of stay, which reflect the nature of the
study design, targeted to reduce adverse events and re-
source consumption. Case series/reports, classically writ-
ten to report unusual or novel occurrences, tended to
report “miscellaneous single outcomes” that were not
studied at a larger scale in cohort or randomized con-
trolled trials.
Table 1 Characteristics of included studies (Continued)
First author (ref.) Year Intervention
type
Intervention Study type Region of
origin
Sample
Size
Short [70] 2016 NP Breastfeeding RCS USA 3725
Patrick [71] 2016 NP Evidence-based practice guidelines QI USA 3458
Kraft [72] 2017 P Buprenorphine RCT USA 63
Zuzarte [73] 2017 NP Vibrotactile stimulation Prospective within-subject
study
USA 26
Grossman [74] 2017 NP Standardization and inpatient unit QI USA 287
Howard [75] 2017 NP Parental presence RCS USA 86
CR case report, CS case series, NP non-pharmacologic, P Pharmacologic, PCS prospective cohort study, QI quality improvement, RCS retrospective cohort study, RCT
randomized controlled trial
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Table 2 Variation in definition of outcomes reported
Outcome Reported outcome definition
Duration of pharmacotherapy (n = 32) Days of opioid treatment
Duration of treatment for NAS symptoms
Duration of pharmacotherapy for NAS/NOWS
Days of treatment
Duration of treatment required for NAS resolution
Number of days on morphine
Duration of opioid treatment
Duration of oral morphine treatment
Length of opioid treatment
Length of methadone therapy
Duration of phenobarbital treatment
Total phenobarbital treatment days
Total treatment duration (hospital + home)
Length of treatment
Days on DTO
Days on any form of pharmacologic support
Duration of hospital stay (n = 31) Days of inpatient hospitalization
Neonatal length of stay
Length of inpatient stay
Duration of hospital stay
Mean infant hospital stay
Average length of stay between hospitals
NICU level of care (n = 8) NICU admission
Length of NICU stay
Admission to level II nursery or chronic care unit
Adverse event—unplanned ICU transfer
Transferred to NICU from inpatient unit
Breastfeeding or human milk nutrition (n = 12) Breastfeeding during hospital stay
Breastfeeding at discharge
Initiation of breastfeeding
Breastfeeding rates 6–8 weeks of age
Rate of breastfeeding
Duration of breast feeding
Breastfeeding
Taking ≥50% of feed as breast milk at discharge
Discharge on human milk
Opioid withdrawal symptoms (n = 24) Neonatal substance withdrawal
Withdrawal symptoms
Time of onset of symptoms
Severity of NAS/NOWS
Average daily score
Mean NAS score
Intensity of withdrawal
Control of withdrawal symptoms
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Table 2 Variation in definition of outcomes reported (Continued)
Outcome Reported outcome definition
Number of times NAS score >8
Mean Finnegan withdrawal scores
Treatment effectiveness
Duration of neonatal abstinence syndrome
Severity of NAS (mean peak NAS)
NAS scores (undefined time point)
Highest Finnegan score
Time to highest Finnegan score
Highest NAS score
Prevalence of symptoms of NAS
Custody at discharge (n = 7) Custody status at discharge
Discharge of babies in the custody of their mothers
Child placed in foster care
Discharge in parental care
Discharge from hospital with their biological family
Dose of pharmacotherapy (n = 18) Total dose (mg/kg) of methadone administered
Range of morphine doses (mg/kg/day)
Morphine doses during the first 38 days of treatment
Maximum morphine dose (mean mg/kg/day)
Initial median opioid dose (methadone or morphine PO)
Cumulative morphine dose
Total opioid dose
Maximum clonidine dose
Highest mean methadone dose given
Amount of DTO required to treat NAS
Mean total morphine dose
Maximum amount of morphine (mL/kg)
Time to maximum amount of oral morphine
Median dosages over time
Average phenobarbital dose
Addition of adjunctive therapy (n = 17) Phenobarbital adjunct therapy
Percentage treated with an adjuvant medication
Adjunct medications
Addition of a second agent (clonidine or phenobarbital)
Amount of pharmacologic support
Addition of a second agent
Initiation of pharmacotherapy (n = 11) Treated with morphine
Pharmacologic treatment for NAS
Need for treatment of NAS
Need for pharmacotherapy with morphine
Percentage of cohort requiring oral morphine
Weight (n = 7) Weight gain
Discharge weight
Weight loss greater than 10% in the first week of life
Shan et al. Trials          (2020) 21:262 Page 8 of 14
Assignment of primary outcomes to OMERACT core areas
One hundred and seven primary outcomes and 127
secondary outcomes were mapped to core domains
defined by OMERACT filter 2.0 in Figure 3 [27].
The core area most commonly studied was “Re-
source Use/Economical Impact” through 72 primary
outcomes and 67 secondary outcomes. This was
followed by “pathophysiological manifestations” cov-
ered by 23 primary outcomes and 26 secondary out-
comes and “life impact” examined by nine primary
outcomes and 15 secondary outcomes. “Adverse
events” were reported as three primary outcomes
and 16 secondary outcomes. “Death” was not re-
ported as a primary outcome in any study and was
reported as three secondary outcomes.
Discussion
This review summarizes the primary and secondary out-
comes that are reported in current primary research
studies (randomized controlled trials, cohort studies,
qualitative analysis, case series, case reports, quality im-
provement studies) of neonates with NAS. We found
substantial heterogeneity in outcomes selected and poor
overall standardization of definitions and timing of
measurement across commonly reported outcomes.
These findings have important implications for clinical
practice and for research as inconsistency in outcome
selection, definition and measurement yields results that
cannot be combined in meta-analyses. For example,
“weight” is used as a proxy for NAS-related feeding con-
cerns in seven studies, but it was defined as “weight
Table 2 Variation in definition of outcomes reported (Continued)
Outcome Reported outcome definition
Time to regain birthweight
Poor weight gain
Time to symptom control (n = 3) Duration of treatment to achieve Lipsitz score below 4
Treatment response
Time to symptom control after initiation of therapy
Cost of treatment (n = 6) Costs for all opioid-exposed infants
Costs for all opioid-exposed infants treated pharmacologically
Average hospital cost per infant
Total cost of treatment
Average total cost of hospitalization (direct and indirect)
Cost-effectiveness
Development (n = 2) Infant neurobehavior
Neurobehavior
Adverse events (n = 14) Safety of noninsertive acupuncture
Neonatal safety (adverse drug reactions)
Safe
Safety (adverse events)
Seizures
Mortality in hospital
Infant death
Unintended side effects
Readmission to hospital (n = 9) Return to hospital for withdrawal treatment
Readmission to hospital
Readmission in 1 week postdischarge
Readmission in the first year of life
Hospital readmission 2 months following discharge
30-day readmissions (all cause)
30-day readmission (withdrawal)
n represents the number of times an outcome category was reported as either a primary or secondary outcome; difference between number of times an outcome
category was reported and the number of articles reporting an outcome category is secondary to the use of composite outcomes
DTO diluted tincture of opium, ICU intensive care unit, NAS neonatal abstinence syndrome, NICU neonatal intensive care unit, NOWS neonatal opioid withdrawal
syndrome, PO per oral, mLmililiters, kg kilograms
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gain”, “discharge weight”, “weight loss greater than 10%
in the first week of life”, “poor weight gain” and “time to
regain birthweight”, jeopardizing comparison and syn-
thesis of study results. This finding further substantiates
the challenge in data synthesis of quantitative data if a
range of time points are utilized to measure one
outcome.
In our systematic review, 47 original research articles
reported 107 primary outcome measures resulting from
the use of composite outcomes. These findings are con-
sistent with a recent overview of Cochrane systematic
reviews in neonatology which found that over half of re-
cent reviews were inconclusive secondary to heterogen-
eity of the literature and poor methodologic quality of
Fig. 2 Outcome matrix of 234 outcome terms (rows) for 47 primary research studies (columns). Red signifies a primary outcome. Blue signifies a
secondary outcome. Green signifies a primary and secondary outcome reported in the same article that fit within the same outcome category.
NAS neonatal abstinence syndrome, NICU neonatal intensive care unit
Table 3 Study design and top three most commonly reported outcome categories
Type of study First most commonly reported outcome
category
Second most commonly reported outcome
category(ies)
Third most commonly reported outcome
category(ies)
Retrospective cohort study
(n = 21)
Duration of hospital stay (16%) NAS symptoms (13%) Duration of pharmacotherapy (12%)
Randomized controlled trial
(n = 10)
Duration of pharmacotherapy (22%) Duration of hospital stay (12%) Adjunctive therapy (10%)
Adverse events (10%)
Prospective cohort study (n =
5)
Dose of pharmacotherapy (22%) Duration of pharmacotherapy (17%) Duration of hospital stay (11%)
NAS symptoms (11%)
Initiation of pharmacotherapy (11%)
Quality improvement (n = 4) Duration of hospital stay (15%) Adverse events (12%) Initiation of pharmacotherapy (8%)
Cost of treatment (12%) Readmission to hospital (8%)
Advancing level of care (NICU admission)
(12%)
Feeding breast milk (8%)
Custody at discharge (8%)
Case series and case report
(n = 4)
Miscellaneous single outcomes (25%) Duration of pharmacotherapy (17%) Duration of hospital stay (8%)
NAS symptoms (17%) Dose of pharmacotherapy (8%)
Adverse events (17%) Adjunctive therapy (8%)
Qualitative study (n = 1) NAS symptoms (100%)
Mixed method (n = 1) Feeding breast milk (100%) NAS symptoms (25%)
Initiation of pharmacotherapy (25%)
Prospective within-subject
study(n = 1)
Miscellaneous single outcomes (100%)
NAS neonatal abstinence syndrome
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the studies [76]. Poor outcome definitions may contrib-
ute to reporting bias. Chan et al. noted that 62% of trials
had primary outcomes changed, introduced or omitted
in the process of protocol to publication [77]. Inconsist-
ently selected and defined outcomes led to results that
are not reproducible, transparent or comparable [78].
Timing of outcome measure was poorly reported across
studies, which may be understandable for outcomes
which measure time (for example, duration of time in
hospital or duration of treatment) but create challenges
for interpreting time-dependent variables such as neuro-
development and withdrawal severity scoring. Training
and descriptions of outcome assessors were poor and,
given the subjective nature of some withdrawal scoring
criteria, this creates barriers for interpretation and repli-
cation. Not only does this contribute to research waste,
but also can create misleading conclusions that clinicians
use to inform patient care.
COSs have been proposed as a method of standardiz-
ing outcome selection, measurement and reporting to
optimize research data in terms of transparency, repro-
ducibility and clinical utility [27, 79, 80]. The absence of
a COS results in: 1) meaningful outcomes (i.e., patient
preferences) being overlooked or lost in study design; 2)
inconsistent definitions or measurement tools used
across similar studies; and 3) choosing outcomes for
publication based on the results of individual studies
(reporting bias) [27, 79, 80]. Thus, establishment of a
COS representing a minimum set of outcomes that must
be measured and reported in all research on NAS inter-
ventions and prognosis is critical to improving research
quality and evidence-informed care. This review is the
first step in a series of methods to develop consensus on
what should be measured in all studies on neonatal
withdrawal. Consistency in reporting would enhance the
value of NAS/NOWS literature by reducing reporting
bias of prespecified outcomes and ensuring that research
efforts contribute clinically relevant information. In
addition, standardization of outcomes would allow trial
results to be compared, contrasted and combined in sys-
tematic reviews and meta-analyses to create a more ro-
bust foundation of knowledge for clinical decision-
making and funding allocation [79].
Furthermore, this study found that outcomes related
to the core area “life impact” are scarce in existing NAS
literature, suggesting that public stakeholder involve-
ment in outcome selection is limited to date. With the
rise of substance use disorders comes an increase in ne-
onates with in utero exposure who are experiencing
NAS/NOWS. Key stakeholders, the parents and care-
givers, are often in a situation of insufficient community
support due to lack of knowledge and awareness about
Fig. 3 Assignment of outcome terms to OMERACT 2.0 core areas. Parentheses show the number of studies in which the outcome was used as
primary outcome/used as secondary outcome. See Table 2 for definitions of adverse events and treatment failure. ER emergency room, NAS
neonatal abstinence syndrome, NICU neonatal intensive care unit
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the life impact of NAS for that infant and family. Most
outcomes reported are related to “resource utilization”
reflecting the increasingly high economic burden of
NAS, the main concern from the policy-maker point of
view. While important, these outcomes do not provide
evidence for clinicians on the optimal care for the infant,
the mother and/or dyad involved. By estimating the bur-
den of NAS based on nearsighted benchmarks such as
“length of hospital stay” or “duration of pharmacother-
apy”, while simplifying the methodology of studies, the
cost to society may be grossly underestimated. There are
still principle variables such as the impact of in utero
opioid exposures on physical health, neurodevelopmen-
tal, psychiatric health and psychosocial interactions of
the growing child that have yet to be explored. How do
these long-term sequelae for the child affect parents,
families and support workers?
Strengths and limitations
The strengths of our study are the inclusion of all pri-
mary research studies, following a preregistered proto-
col, and methods following the PRISMA guidelines [81].
A comprehensive search of the bibliographies for the
studies included and recent systematic reviews was
undertaken to identify any articles missed in our search
strategy. Furthermore, the steering committee reviewed
the list of included articles and were invited to suggest
articles that were not identified using our search strat-
egy. The main limitations to our review are the time
boundaries of 2007–2017 for the search strategy and
most included studies reported data from western coun-
tries which may limit external validity. This is, however,
a limitation of the literature available and we do not feel
this is related to our search or selection process. In this
review, we did not contact the research groups for miss-
ing information. The aim of our study was to abstract
primary and secondary outcomes and, as such, we did
not intend to assess the rigor to which the studies re-
ported this information as missing data are unlikely to
affect the conclusions formulated here.
The conclusions from this systematic review advocate
for the formation of a COS for NAS/NOWS to establish
consistently reported outcomes with standardized defini-
tions. Other COSs and studies have demonstrated that
public involvement leads to research that is comprehen-
sive and relevant to the patients receiving evidence-
based interventions [82]. Since 2010, the COMET initia-
tive has set out to establish standardized sets of out-
comes for intervention clinical trials and clinical audits
[83]. Their overarching objective is to limit outcome het-
erogeneity, include relevant outcomes, and reduce out-
come reporting bias through the development of COSs.
Trials evaluating the effectiveness of a treatment should
measure and report at least each outcome in the COS.
However, the primary outcome should be chosen and
powered to answer the research question. COS develop-
ment should be comprehensive and include outcomes
relevant for multiple stakeholders from patients/families,
clinicians and scientists.
Recent expert reviews in the Journal of the American
Medical Association [28] and the New England Journal
of Medicine [3] concluded several areas of uncertainty
including standardized and validated assessment tools,
optimal medication treatment regimen, optimal location
for weaning, long-term neurodevelopment and family
outcomes in NAS/NOWS that require further research.
Given the heterogeneity in outcome selection, measure-
ment and reporting highlighted by this study, it is im-
perative and timely to devise a COS for NAS/NOWS. A
NAS/NOWS COS will standardize research method-
ology to reduce research waste and enhance transpar-
ency for clinical decision-making. With a scarcity of
knowledge on the long-term patient and family impact
of NAS/NOWS, the COS should reflect the needs and
concerns for the stakeholders that are most affected by
this condition. A consensus and evidence-based NAS/
NOWS COS is underway led by a multidisciplinary
international steering committee. The development of
this COS includes family interviews to ensure that future
studies will evaluate outcome measures that are mean-
ingful to the population it affects the most.
Conclusion
Inconsistent selection and definition of primary and sec-
ondary outcomes exists in the literature of pharmaco-
logic and nonpharmacologic interventions for managing
opioid withdrawal in neonates. No studies involved par-
ents in the process of outcome selection. These findings
hinder evidence synthesis to generate clinically meaning-
ful practice guidelines. The development of a specific
COS reflecting the needs of stakeholders, including fam-
ilies, is required to improve the quality of clinical prac-
tice guidelines.
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